

# **PREDICTIVE: Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation - Longitudinal Study on Diabetic Patients Treated with Detemir Insulin**

Head :Marre Michel, Unité 695 : Déterminants génétiques du diabète de type 2 et de ses complications vasculaires

Last update : 05/12/2015 | Version : 3 | ID : 8954

General	
Identification	
Detailed name	Longitudinal Study on Diabetic Patients Treated with Detemir Insulin
Sign or acronym	PREDICTIVE: Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL
General Aspects	
Medical area	Endocrinology and metabolism
Health determinants	Genetic
Keywords	analogue, detemir insulin, efficacy, tolerance
Scientific investigator(s) (Contact)	
Name of the director	Marre
Surname	Michel
Address	Faculté de Médecine Xavier Bichat 16 rue Henri Huchard 75870 Paris Cedex 18
Phone	+33 (0)1 44 85 62 28
Email	michel.marre@bch.aphp.fr
Unit	Unité 695 : Déterminants génétiques du diabète de type 2 et de ses complications vasculaires

Organization	Inserm
Collaborations	
Funding	
Funding status	Private
Details	- Novo Nordisk A/S.
Governance of the database	
Sponsor(s) or organisation(s) responsible	Institut National de la Santé et de la Recherche Médicale - Inserm
Organisation status	Public
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Longitudinal study (except cohorts)
Database recruitment is carried out by an intermediary	A selection of health care professionals
Database recruitment is made on the basis of:	Another treatment or procedure
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	At the discretion of the treating physician.
Database objective	
Main objective	To investigate the effect of using determir insulin in normal clinical practice.
Inclusion criteria	<ul style="list-style-type: none"> <li>- Male and female;</li> <li>- Adult;</li> <li>- Diabetic (type 1 and 2);</li> <li>- Treated with determir insulin.</li> </ul>
Population type	

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	International
Detail of the geography area	Europe (Austria, Denmark, France, Germany, Ireland, Turkey, United Kingdom).
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2006
Size of the database	
Size of the database (number of individuals)	[1000-10 000[ individuals
Details of the number of individuals	19,911 (Europe): - France (1,772): - 643 patients with type 1 diabetes - 1,129 patients with type 2 diabetes.
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Biological data
Clinical data (detail)	Direct physical measures
Details of collected clinical data	--
Biological data (detail)	Glycaemic control
Presence of a biobank	No
Health parameters studied	Health event/morbidity
Procedures	
Participant monitoring	Yes

Details on monitoring of participants	Visits at baseline, 12 weeks, 26 weeks and 52 weeks.
Links to administrative sources	No
Promotion and access	
Promotion	
Link to the document	<a href="http://tinyurl.com/Pubmed-PREDICTIVE">http://tinyurl.com/Pubmed-PREDICTIVE</a>
Description	List of publications in Pubmed
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Contact the scientist in charge.
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only